{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:29:29Z","timestamp":1779910169885,"version":"3.53.1"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ovarian cancer remains the most lethal gynecologic malignancy due to strong interpatient heterogeneity and immune evasion. Traditional two-dimensional cultures and animal models lack the ability to maintain interactions among tumors, immune cells, and stromal cells and have limitations in clinical translation. This review discusses the organoid construction methods using adult stem cells (normal epithelium, tumor tissues and ascites), and induced pluripotent stem cells, comparing various culture platforms from air\u2013liquid interface to microfluidic devices. We highlight organoids containing immune components are valuable for assessing T cell exhaustion, NK cell cytotoxicity, and stromal communication, which help to screen immunotherapy, discover biomarker, and profile drug resistance. The persistent challenges include limited vascularization, short-term maintenance of immune components and lack of standard protocols. We present new solutions that integrate multi-omics, biomaterials and automated perfusion to improve physiological fidelity and scalability. Collectively, ovarian cancer organoids with immune microenvironment can bridge preclinical gaps and accelerate the development of personalized immune therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1773734","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:48:38Z","timestamp":1773298118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering immune-competent niches: strategies, applications, and translational hurdles in ovarian cancer organoid models"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuying","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[{"name":"Academic Affairs Office, Jilin Medical University","place":["Jilin, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxin","family":"Dong","sequence":"additional","affiliation":[{"name":"Changchun Veterinary Research Institute, Chinese Academy of Agricultural Science","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensen","family":"Liu","sequence":"additional","affiliation":[{"name":"Changchun Veterinary Research Institute, Chinese Academy of Agricultural Science","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangchao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy","volume":"52","author":"Jim\u00e9nez-S\u00e1nchez","year":"2020","journal-title":"Nat Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09240-3","article-title":"Ongoing genome doubling shapes evolvability and immunity in ovarian cancer","volume":"644","author":"McPherson","year":"2025","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09580-0","article-title":"Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA","volume":"647","author":"Williams","year":"2025","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232323373240905104033","article-title":"Characteristics of oxidative phosphorylation-related subtypes and construction of a prognostic signature in ovarian cancer","volume":"25","author":"Lu","year":"2025","journal-title":"Curr Gene Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232417125251021114250","article-title":"Foxp3+ Tregs promote M2 macrophage polarization via sirt1-ERK1\/2-STAT3 pathway in ovarian cancer progression","author":"Liang","year":"2025","journal-title":"Curr Gene Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429263063231204095516","article-title":"Anticancer Properties of Baicalin against Breast Cancer and other Gynecological Cancers: Therapeutic Opportunities based on Underlying Mechanisms","volume":"17","author":"Pourhanifeh","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/0109298665351592250106062250","article-title":"ZNF165: A pan-cancer biomarker with prognostic and therapeutic potential","volume":"32","author":"Lyu","year":"2025","journal-title":"Protein Pept Lett"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ben-David","year":"2017","journal-title":"Nat Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ygyno.2015.08.017","article-title":"Beyond genomics: critical evaluation of cell line utility for ovarian cancer research","volume":"139","author":"Elias","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw6985","article-title":"Cancer modeling meets human organoid technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0455","article-title":"Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.697","article-title":"Patient-derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin","volume":"5","author":"Zhao","year":"2024","journal-title":"MedComm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1802","article-title":"Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy","volume":"14","author":"Chen","year":"2024","journal-title":"Clin Trans Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10741","DOI":"10.1038\/s41598-017-05519-2","article-title":"Directed differentiation of human induced pluripotent stem cells into fallopian tube epithelium","volume":"7","author":"Yucer","year":"2017","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110146","article-title":"Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis","volume":"37","author":"Yucer","year":"2021","journal-title":"Cell Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced pluripotent stem cells in disease modelling and drug discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature13863","article-title":"Modelling human development and disease in pluripotent stem-cell-derived gastric organoids","volume":"516","author":"McCracken","year":"2014","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf9414","article-title":"Human tissues in a dish: The research and ethical implications of organoid technology","volume":"355","author":"Bredenoord","year":"2017","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41698-025-01251-7","article-title":"Large scale quantification of natural killer cell-induced apoptosis in patient-derived organoids reveals intratumoral response heterogeneity","volume":"10","author":"Mercadante","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1291559","article-title":"Modeling of senescence-related chemoresistance in ovarian cancer using data analysis and patient-derived organoids","volume":"13","author":"Cai","year":"2024","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-00474-1","article-title":"Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids","volume":"16","author":"Dekkers","year":"2021","journal-title":"Nat Protoc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00018-023-04906-5","article-title":"AUF1-induced circular RNA hsa_circ_0010467 promotes platinum resistance of ovarian cancer through miR-637\/LIF\/STAT3 axis","volume":"80","author":"Wu","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/s12885-024-12429-w","article-title":"The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers","volume":"24","author":"Thorel","year":"2024","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189052","article-title":"The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models","volume":"1879","author":"Tadi\u0107","year":"2024","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104013","article-title":"Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment","volume":"39","author":"Hoffmann","year":"2020","journal-title":"EMBO J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0248-y","article-title":"Organoids in immunological research","volume":"20","author":"Bar-Ephraim","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2020.05.002","article-title":"Organoid technology and applications in cancer immunotherapy and precision medicine","volume":"65","author":"Homicsko","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","article-title":"Tumor organoid-T-cell coculture systems","volume":"15","author":"Cattaneo","year":"2020","journal-title":"Nat Protoc"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1170-8","article-title":"Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes","volume":"51","author":"Nozaki","year":"2016","journal-title":"J Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19965","article-title":"Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures","volume":"8","author":"Finnberg","year":"2017","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.06.010","article-title":"Organoid models of tumor immunology","volume":"41","author":"Yuki","year":"2020","journal-title":"Trends Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","article-title":"Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids","volume":"8","author":"Jenkins","year":"2018","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcdb.2022.10.001","article-title":"Microfluidic organoids-on-a-chip: The future of human models","volume":"144","author":"Saorin","year":"2023","journal-title":"Semin Cell Dev Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1216989110","article-title":"Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules","volume":"110","author":"Rizvi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/srep26788","article-title":"Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress","volume":"6","author":"Ip","year":"2016","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1043117","article-title":"3D organ-on-a-chip: The convergence of microphysiological systems and organoids","volume":"10","author":"Baptista","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2013.125","article-title":"Three-dimensional cell culturing by magnetic levitation","volume":"8","author":"Haisler","year":"2013","journal-title":"Nat Protoc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2010.23","article-title":"Three-dimensional tissue culture based on magnetic cell levitation","volume":"5","author":"Souza","year":"2010","journal-title":"Nat Nanotechnol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/2472555216687082","article-title":"A high-throughput screening model of the tumor microenvironment for ovarian cancer cell growth","volume":"22","author":"Lal-Nag","year":"2017","journal-title":"SLAS Discov"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202000721","article-title":"Biofabrication of a functional tubular construct from tissue spheroids using magnetoacoustic levitational directed assembly","volume":"9","author":"Parfenov","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","article-title":"A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids","volume":"58","author":"Senkowski","year":"2023","journal-title":"Dev Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12967-025-07112-y","article-title":"Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer","volume":"24","author":"Wang","year":"2026","journal-title":"J Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2020.03.004","article-title":"Developing organoids from ovarian cancer as experimental and preclinical models","volume":"14","author":"Maenhoudt","year":"2020","journal-title":"Stem Cell Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072162","article-title":"Type-specific cell line models for type-specific ovarian cancer research","volume":"8","author":"Anglesio","year":"2013","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.05.005","article-title":"Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors","volume":"154","author":"Maru","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1039\/c8lc00322j","article-title":"3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade","volume":"18","author":"Aref","year":"2018","journal-title":"Lab Chip"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-022-00827-w","article-title":"Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs","volume":"36","author":"Ito","year":"2023","journal-title":"Hum Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41580-020-0278-0","article-title":"Cell fate specification and differentiation in the adult mammalian intestine","volume":"22","author":"Beumer","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41467-020-16432-0","article-title":"Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids","volume":"11","author":"L\u00f5hmussaar","year":"2020","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6521","article-title":"Patient-derived organoid culture in epithelial ovarian cancers\u2014Techniques, applications, and future perspectives","volume":"12","author":"Chan","year":"2023","journal-title":"Cancer Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01899-z","article-title":"Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer","volume":"127","author":"Nicholson","year":"2022","journal-title":"Br J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-021-01085-1","article-title":"A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids","volume":"21","author":"Below","year":"2022","journal-title":"Nat Mater"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41467-020-14869-x","article-title":"Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation","volume":"11","author":"Ji","year":"2020","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ccell.2025.06.004","article-title":"Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression","volume":"43","author":"Schweizer","year":"2025","journal-title":"Cancer Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.718834","article-title":"Substrate stiffness modulates the growth, phenotype, and chemoresistance of ovarian cancer cells","volume":"9","author":"Fan","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s42003-021-02910-8","article-title":"Towards organoid culture without Matrigel","volume":"4","author":"Kozlowski","year":"2021","journal-title":"Commun Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00808","article-title":"Decellularized extracellular matrix-based bioinks for engineering tissue- and organ-specific microenvironments","volume":"120","author":"Kim","year":"2020","journal-title":"Chem Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nature20168","article-title":"Designer matrices for intestinal stem cell and organoid culture","volume":"539","author":"Gjorevski","year":"2016","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/adf099","article-title":"Engineered tumor microspheres via microfluidics and decellularized extracellular matrix for high-throughput organoid-based drug screening","volume":"17","author":"Jin","year":"2025","journal-title":"Biofabrication"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2020.11.009","article-title":"Development of a single-cell technique to increase yield and use of gastrointestinal cancer organoids for personalized medicine application","volume":"232","author":"Gao","year":"2021","journal-title":"J Am Coll Surg"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115081","article-title":"Probing organoid metabolism using fluorescence lifetime imaging microscopy (FLIM): The next frontier of drug discovery and disease understanding","volume":"201","author":"Barroso","year":"2023","journal-title":"Advanced Drug Delivery Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103280","article-title":"Predicting DNA damage response in non-small cell lung cancer organoids via simultaneous label-free autofluorescence multiharmonic microscopy","volume":"75","author":"Roh","year":"2024","journal-title":"Redox Biol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.stem.2020.02.007","article-title":"Genome-scale CRISPR screening in human intestinal organoids identifies drivers of TGF-\u03b2 Resistance","volume":"26","author":"Ringel","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-018-0662-9","article-title":"Organoid technology and applications in cancer research","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16547","article-title":"CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"B81","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1038\/s41467-020-20140-0","article-title":"Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages","volume":"11","author":"Song","year":"2020","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1674","article-title":"Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer","volume":"81","author":"Wan","year":"2021","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1969075","article-title":"Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response","volume":"10","author":"Cao","year":"2021","journal-title":"Oncoimmunology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2340186","DOI":"10.2144\/fsoa-2023-0135","article-title":"Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids","volume":"10","author":"Zhu","year":"2024","journal-title":"Future Sci OA"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2288","article-title":"Targeting of cancer neoantigens with donor-derived T cell receptor repertoires","volume":"352","author":"Str\u00f8nen","year":"2016","journal-title":"Science"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-6614892\/v1","article-title":"Tumoroid model recreates clinically relevant phenotypes of high grade serous ovarian cancer (HGSC) cells, carcinoma associated fibroblasts, and macrophages","author":"Burkhard","year":"2025"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2537710","article-title":"Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response","volume":"14","author":"Nikeghbal","year":"2025","journal-title":"OncoImmunology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072059","article-title":"Patient derived organoids (PDOs), extracellular matrix (ECM), tumor microenvironment (TME) and drug screening: state of the art and clinical implications of ovarian cancer organoids in the era of precision medicine","volume":"15","author":"Spagnol","year":"2023","journal-title":"Cancers"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102523","article-title":"Patient-derived extracellular matrix from decellularized high-grade serous ovarian carcinoma tissues as a biocompatible support for organoid growth","volume":"61","author":"Sensi","year":"2025","journal-title":"Trans Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214173","article-title":"Akt-activated endothelium increases cancer cell proliferation and resistance to treatment in ovarian cancer cell organoids","volume":"23","author":"Hoarau-V\u00e9chot","year":"2022","journal-title":"IJMS"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217738","article-title":"A necrosis inducer promotes an immunogenic response and destroys ovarian cancers in mouse xenografts and patient ascites organoids","volume":"625","author":"Duraki","year":"2025","journal-title":"Cancer Lett"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156721","article-title":"Zengmian Yiliu formula suppresses cell cycle in immune-rich ovarian cancer patient-derived organoids","volume":"141","author":"Cao","year":"2025","journal-title":"Phytomedicine"},{"key":"B94","doi-asserted-by":"publisher","first-page":"9983","DOI":"10.1038\/s41598-022-13930-7","article-title":"Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy","volume":"12","author":"Shelkey","year":"2022","journal-title":"Sci Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003000","article-title":"Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids","volume":"9","author":"Hamdan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2080-8","article-title":"Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli","volume":"580","author":"Pleguezuelos-Manzano","year":"2020","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01438-14","article-title":"Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids","volume":"5","author":"Lukovac","year":"2014","journal-title":"mBio"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0397-0","article-title":"A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip","volume":"3","author":"Jalili-Firoozinezhad","year":"2019","journal-title":"Nat BioMed Eng"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11535","article-title":"A microfluidics-based in vitro model of the gastrointestinal human-microbe interface","volume":"7","author":"Shah","year":"2016","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses","volume":"31","author":"de Witte","year":"2020","journal-title":"Cell Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115238","article-title":"Bioengineering toolkits for potentiating organoid therapeutics","volume":"208","author":"Park","year":"2024","journal-title":"Advanced Drug Delivery Rev"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155447","article-title":"Tissue-specific decellularization methods: rationale and strategies to achieve regenerative compounds","volume":"21","author":"Mendibil","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102130","article-title":"Exploration of organoids in ovarian cancer: From basic research to clinical translation","volume":"50","author":"Li","year":"2024","journal-title":"Trans Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201000340","article-title":"A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform","volume":"6","author":"Xu","year":"2011","journal-title":"Biotechnol J"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw7894","article-title":"Organoids-on-a-chip","volume":"364","author":"Park","year":"2019","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/science.1188302","article-title":"Reconstituting organ-level lung functions on a chip","volume":"328","author":"Huh","year":"2010","journal-title":"Science"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175824","article-title":"FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI\/ML-based approaches","volume":"133","author":"Zushin","year":"2023","journal-title":"J\u00a0Clin Invest"},{"key":"B108","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114507","article-title":"Organ-on-a-chip: Quo vademus? Applications and regulatory status","volume":"249","author":"Mendes","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01326-2","article-title":"The gut microbiota in cancer immunity and immunotherapy","volume":"22","author":"Xie","year":"2025","journal-title":"Cell Mol Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:48:40Z","timestamp":1773298120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":110,"alternative-id":["10.3389\/fimmu.2026.1773734"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1773734","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1773734"}}